Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...

Ten out of 11 children with a form of congenital deafness who were treated with an experimental gene therapy developed by ...

Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the rare autoimmune skin disorder bullous pemphigoid (BP). The US Food ...

Regeneron Pharmaceuticals (NASDAQ:REGN) is one of the leaders in the ophthalmic disease therapeutics market. In this article, dear Seeking Alpha readers, I present five factors that explain why I ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...

Regeneron reported Q4 2024 earnings today - revenues were up 10% YoY to $3.79bn. Full-year revenues were up 8% to $14.2bn. Q4 GAAP EPS at $8.06, and $38 adj. full-year. The company declared its ...

Feb 4 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and ...

SOPA Images / Contributor / Getty Images Teva Pharmaceutical ... The treatment is a biosimilar that could compete with Regeneron Pharmaceuticals’ Eylea. Teva and Alvotech have been working ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in ...

Regeneron posted Q4 adjusted EPS of $12.07, beating the $11.29 consensus. Sales rose 10% to $3.79B, surpassing the $3.75B estimates. Eylea HD and Eylea U.S. sales grew 2% Y/Y to $1.49B, while ...